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ABSTRACT We have characterized the promoter of the
mouse retinoic acid receptor a2 (mRAR-a2) isoform. This
promoter contains a retinoic acid response element (RARE)
that closely resembles the RARE that is present in the RAR-f82
promoter. Moreover, RAR-a2 and RAR-fl2 proximal pro-
moter sequences are similar to each other and generate tran-
scripts whose respective start sites are located at similar
positions. The RAR-a2 RARE consists of two directly repeated
5'-GTTCA-3' motifs to which all three RARs (a, (3, and y) bind
in vitro.
The highly pleiotropic effects of retinoic acid (RA), a major
developmental signaling molecule, are mediated by the prod-
ucts of three nuclear receptor genes (RAR-a, -(3, and -y),
which interact with cis-acting RA response elements
(RAREs) present in the promoter ofRA target genes, thereby
modulating their transcription (refs. 1 and 2 and references
therein). Each subtype gene encodes several isoforms that
are generated by alternative splicing of primary transcripts
initiated from either one oftwo promoters. A previous report
(3) showed that the mRNA level of RAR-a2, one of the two
major RAR-a isoforms, is markedly increased in murine F9
and P19 embryonal carcinoma (EC) cells upon RA treatment.
We have now characterized the promoter that generates this
isoform and demonstrate here that it contains a RARE.t
MATERIALS AND METHODS
Mapping of the Mouse mRAR-a2 (mRAR-a2) Transcrip-
tion Start Site. A 1.4-kilobase (kb) EcoRI-Xho I fragment
derived from phage AG3 mRAR-a (3) was subcloned into the
pBluescript SKII(+) vector (Stratagene) to yield the recom-
binant pEX, of which the 1.3-kb Xba I-Xho I segment was
sequenced (Fig. 1A). The location of the mRAR-a2 start site
was determined as described (4) by primer extension using
the 5'-end-labeled antisense primer OY113 (Fig. 1A) and total
RNA isolated from RA-treated (1 ,uM) P19 EC cells (Fig. 1B).
Reporter Genes for mRAR-a2 Promoter Activity. The Xba
I-Xho I mRAR-a genomic DNA fragment was inserted in the
Xba I and Xho I sites of the chloramphenicol acetyltrans-
ferase (CAT) reporter plasmid pBLCAT3 (6). The pBLCAT3
polylinker Pst I and Sph I sites were eliminated by digestion
with HindIII and Xba I, followed by blunt-end ligation, which
restored an Xba I site and yielded RAR-a2/CAT1 containing
unique Pst I and Sph I sites (Fig. 2A). RAR-a2/CAT1 was
digested with Pst I and Xho I, and the DNA ends were
filled-in, yielding RAR-a2/CAT2 after ligation. RAR-a2/
CAT3 and RAR-a2/CAT4 were obtained by inserting the
549-bp Pst I-Xho I fragment and the 859-bp Sph I-Xho I
fragment of pEX into the corresponding sites of pBLCAT3
(Fig. 2A). RAR-a2ml/CAT1 was engineered from RAR-a2/
CAT1 by introducing six transversions into the a2 RARE
through PCR-assisted site-specific mutagenesis with four
primers. The sequence of the two complementary "central"
mutant primers corresponded to that of the a2 RARE ml
oligonucleotide (Fig. 3A). The two "external" primers were
as follows: sense 5' primer, 5'-GGACACC CAATICTG-
CATTCGTG-3'; antisense 3' primer, 5'-ATCCCCTGCAGL-
GAAGATGCAGCGGC-3' (nucleotides -258 to -234 and
nucleotides +48 to +72, respectively; see Fig. 1A; the unique
Sph I and Pst I restriction sites are underlined). PCR reac-
tions were as described (7) and the final PCR product was
digested with Sph I and Pst I. This mutated Sph I-Pst I
cassette (Fig. 1A, -245 to +66) was exchanged with the
corresponding Sph I-Pst I fragment of RAR-a2/CAT1 to
yield RAR-a2ml/CAT1. a2RARE/tk-CAT, a2RAREml/tk-
CAT, a2RAREm2/tk-CAT, and a2RAREm3/tk-CAT were
constructed by inserting the synthetic oligonucleotides a2
RARE, a2 RARE ml, a2 RARE m2, and a2 RARE m3
between the HindIII and Xba I restriction sites of
pBLCAT8+ (8). Other materials and methods were as de-
scribed previously (9, 10).
RESULTS
Isolation of the mRAR-a2 5' Flanking Region and Mapping
of the Start Site ofmRAR-a2 Transcripts. The 18-kb genomic
DNA insert of clone AG3 mRAR-a contains a single Xho I
restriction site, which is also present in the 5' UTR of the
mRAR-a2 cDNA isoform (3). The sequence ofa 1323-bp Xba
I-Xho I fragment that hybridized to mRAR-a2-specific
cDNA sequences was determined (Fig. 1A). As expected, its
3' extremity overlaps with the 5' UTR of the cloned
mRAR-a2 cDNA sequence. The more-upstream genomic
sequences contain recognition sites for rare-cutting restric-
tion enzymes generally associated with CpG islands in mam-
malian genomes (ref. 11 and references therein), which
suggests that this region contains the RAR-a2 start site.
The 5' end of exon E3, which encodes the A region and the
entire 5' UTR of mRAR-a2 (3), was determined by PCR
analysis of mRAR-a2 transcripts and primer extension. PCR
was carried out with cDNA generated by reverse transcrip-
tion [using the mRAR-a2 5'-UTR-specific antisense primer
5'-AAGTTGTGCAGGTTGGAGGA-3' (3)] from poly(A)+
RNA of RA-treated P19 EC cells and one of five oligonucle-
otide primers (Fig. 1A, arrows 1-5) together with a common
3' primer (arrow 6). In all five cases, a specific PCR product
of the expected size was detected (data not shown), indicat-
ing that the 5' border of exon E3 was located upstream from
Abbreviations: UTR, untranslated region; RA, retinoic acid; RAR,
RA receptor; mRAR, mouse RAR; hRAR, human RAR; RARE, RA
response element; CAT, chloramphenicol acetyltransferase; tk, thy-
midine kinase; EC, embryonal carcinoma.
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FIG. 1. Mapping of the mRAR-a2 start site. (A) Sequence of the mRAR-a2 promoter. The sequence of a 1323-base-pair (bp) Xba I-Xho I
DNA fragment of the mRAR-a2 gene was determined on both strands by the standard chain-termination procedure (4). Position + 1 corresponds
to themRNA start site (bent arrow). The 5' boundary ofthe published mRAR-a2cDNA (3) is indicated by a bracket at nucleotide 592. Six possible
binding sites for factor Spl are boxed. The a2 RARE is bracketed and the 5'-GTTCA-3' motifs are indicated by two arrows. The sequence
5'-TGGGTGGGTCA-3' (see text) is underlined with a striped bar. The sequence and orientation of the oligonucleotide (OY113) used for primer
extension are indicated by an arrow (nucleotides +68 to +97). Arrows 1-6 indicate the positions of primers used for PCR analysis of mRAR-a2
transcripts (see text). UTR, untranslated region. (B) Mapping of the mRAR-a2 start site by primer extension. The sequence presented on the
top corresponds to the noncoding strand and the broken arrow indicates position +1. Lanes G, A, T, and C contained sequencing "ladders"
primed with the antisense oligonucleotide 5'-CCAGCCTCCCTAGTGCT-3' and electrophoresed through (left to right as shown here) urea/8%
polyacrylamide gel alongside primer extension products obtained with either total RNA from RA-treated P19 EC cells (P19, two different RNA
preparations) of yeast tRNA (tRNA). (C) Alignment of the sequences of mRAR-a2, human RAR-a2 (hRAR-a2), and mRAR-.82 promoters and
5' UTRs. Gaps have been introduced for optimal alignment; colons indicate identical nucleotides. The nucleotides in the hRAR-a2 DNA
sequence (unpublished results) that differ from the corresponding mRAR-a2 sequences are indicated. RARE directly repeated motifs are boxed.
A putative TATA box in the mRAR-,B2 promoter (5) is indicated, and the sequence 5'-ATTAGGCAA-3', shared by both the RAR-a2 and RAR-,82
promoters, is underlined with a black bar. Other symbols are as in A.
the most 5' PCR primer 1 (Fig. 1A), and that no intron was
interrupting this 5' UTR. Primer extension was then per-
formed to map the 5' end of exon E3 (Fig. 1B), generating a
specific extended fragment whose 5' end mapped at the
position indicated as +1 in Fig. 1.
mRAR-a2 and mRAR-(82 Proximal Promoter Sequences
Are Similar. The mRAR-a2 5' region contains several puta-
tive binding sites for the transcription factor Spl (boxed in
Fig. 1A), located in either the 5' UTR or the proximal
promoter sequences. No obvious TATA- or CCAAT-box
sequences were noticed. However, a sequence closely re-
sembling the RARE previously characterized in the mouse
and human RAR-,B2 promoters (12, 13) lies upstream of the
cap site (Fig. 1 A and C, nucleotides -54 to -39). This
putative RARE consists of a direct repeat of 5'-GTTCA-3'
with a 6-nucleotide spacer whose sequence differs from that
of the 132 RARE. Interestingly, this presumptive RARE is
located at a position (with respect to the cap site) that is
similar to that of (2 RARE.
A comparison between the mRAR-a2 and mRAR-,B2 (5)
proximal promoter sequences reveals that the two sequences
are closely related (Fig. 1C). The sequence 5'-ATTAG-
GCAA-3' located 10 bp downstream ofthe putative a2 RARE
is identical to a sequence located at an equivalent position in
the mRAR-,32 promoter (black bar in Fig. 1C), where it
partially overlaps the RAR-/2 TATA box (5, 12, 13). This
observation, and the fact that RAR-a2 and RAR-,82 start sites
are located at the same position within their respective
genomic DNA sequences (13), suggests that this sequence,
which is conserved in the hRAR-a2 promoter (see Fig. 1C),
corresponds to a RAR-a2 degenerate TATA box. In fact, a
mutation converting this 5'-ATTAGGCAA-3' motif to 5'-
CGACGGCAA-3' resulted in an +70% reduction in the
activity of the mRAR-a2 promoter (data not shown). The
similarity between mRAR-a2 and
-,(2 5' flanking sequences
extends further upstream from the RARE, which suggests
that additional upstream regulatory elements may be com-
mon to both promoters. No mRAR-P2 5' flanking sequences
located further upstream have been reported (5), but further
5' human RAR-f32 DNA sequences have been published (14),
exhibiting no significant similarities with the mRAR-a2 se-
quences located upstream from position -128.
The mRAR-a2 Promoter Is Active in Cultured Cells and
Contains a Functional RARE. Various lengths of the putative
mRAR-a2 promoter sequences were ligated to the CAT gene
(Fig. 2A) and tested for RA inducibility in P19 EC cells. Fig.
2B shows the results of a typical experiment in which CAT
reporter plasmids were transfected into P19 EC cells, which
were subsequently treated with 1 ,uM RA or vehicle (etha-
nol). The promoterless vector pBLCAT3 was inactive (Fig.
2B, lanes 1 and 2); in contrast, RAR-a2/CAT1 showed a low
basal level of CAT activity in the absence of RA and was
induced '20-fold in the presence of 1 ,M RA (lanes 3-6), to
a level similar to that achieved with a RAR-,B2 promoter CAT
reporter (RAR-(32/CAT; see ref. 15). RAR-a2/CAT3 activity
(lanes 11 and 12) was much lower and close to that of
pBLCAT3, whereas RAR-a2/CAT2 (lanes 9 and 10) and
RAR-a2/CAT4 (lanes 13 and 14) activities were similar to
that of RAR-a2/CAT1 (lanes 3 and 4), showing that the
sequences required for RAR-a2 promoter basal activity and
those conferring RA responsiveness are contained within the
245-bp segment located upstream from the start site (Sph I
site at -245 in Fig. 2A).
No RAR expression vectors were cotransfected in these
experiments, indicating that RA induction was mediated by
P19 cell-endogenous RARs (3, 5, 16). That RXRs (17), which
I11 1.ISIE INi in ins I:
.. .1.11-. ,..I
,.w
_-
*f * z
Biochemistry: Leroy et A
10140 Biochemistry: Leroy et al.
A
(-708) 1 +1 '6
RAR-a2/CAT1
B
1323 bp
Xbal Sohl +lro7(Pstl,/h~oll)
,Pstl Xhol
549 bp XJ
Sahl +1 r" Pstl Xpo
RAR-a2/CAT2
.RAR-a2/CAT3
RAR-a2/CAT4
AA
R C- oj lr
HA - - - - - -
+
-
+
* * *
1 2 3 4 5 6 7 8 9 10 11 12 13 14
C
100
.1
C)
a)
.76
-0*OO4k . i...
I @@@-**4b .g !~
I ZJ;- 4 + 3
RAR-cI2YCAT !
50- X
/
/
O0 T f-~ -r-- --~ - -.1100 19 10-8 10-7 1610 l
Retinoic Acid (M)
FIG. 2. RA inducibility of the mRAR-a2 promoter. (A) Schematic
representation of the reporter constructs. mRAR-a2 gene sequences
(sizes in base pairs) and the parental vector pBLCAT3 are repre-
sented as black boxes and broken white segments. Relevant restric-
tion sites are indicated together with their positions with respect to
the start site (+ 1). (B) Representative assay of CAT activity.
Transfections into P19 EC cells were carried out with the constructs
(5 ug) depicted in A (lanes 3 and 4 and 9-14), as well as with the
promoterless pBLCAT3 (5 ,ug) (lanes 1 and 2). A similar construct
containing the mRAR-/32 promoter (RAR-/82/CAT; lanes 5 and 6)
and RAR-a2ml/CAT1, which carries a mutated RARE (lanes 7 and
8; see a2 RARE ml sequence in Fig. 3A), were similarly assayed.
Transfections were done in duplicate in the presence of 10-6 M RA
(+, even lane numbers) or vehicle (ethanol) (-, odd lane numbers).
(C) RA dose-response for RAR-a2/CAT1 activity. RAR-a2/CAT1-
transfected P19 EC cells were treated with either vehicle (ethanol) or
RA (10-10 to 10-6 M) as indicated. The relative CAT activity
(expressed as percent maximal induction in treated versus untreated
cells, average of two independent experiments, solid and open
circles) is plotted against RA concentration. (Inset) A typical assay
in which P19 EC cells were transfected with 5 ,ug of plasmid
RAR-a2/CAT1 (+) and then treated with 10-10, 10-9, 10-8, 1o-7,
and 10-6 M RA (lanes 4-8, respectively) or untreated (lane 3). A
control experiment (-) was carried out with the parental plasmid
pBLCAT3 (5 gig), in the presence (lane 2) or absence (lane 1) of 10-6
M RA.
are also present in P19 cells (P. Kastner and P.C., unpub-
lished observation), could be involved in this induction is
unlikely, since a response was seen with as little as 0.1 nM RA
(Fig. 2C), a concentration at which RXRs do not respond
(17). The same dose-response curve as that shown in Fig. 2C
was obtained with mRAR-/82/CAT (data not shown).
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FIG. 3. Activity of a synthetic a2 RARE on the thymidine kinase
(tk) promoter. (A) Oligonucleotides containing either the wild-type
a2 RARE, or a mutated sequence (a2 RARE ml, m2, and m3) of the
a2 RARE, or the 32 RARE (132 RARE) were ligated into the CAT
expression vector pBLCAT8+. Solid circles indicate mutated bases
in either one of the directly repeated motifs I or II. All other symbols
are as in Fig. 1. (B) The constructs depicted in A were transfected (5
lag) into P19 EC cells along with 250 ng of either the parental
expression vector pSG5 (lanes 1-6) or the mRAR-al expression
vector (lanes 7-18), as indicated. Transfected cells were exposed
either to no ligand (-, odd lane numbers) or to 1 ILM RA (+, even
lane numbers) for 24 hr.
To prove that the above putative RARE (Fig. 1 A and C)
was responsible for RA induction, the activity of the mutant
RAR-a2ml/CAT1 (Materials and Methods) was tested in
transfection experiments (Fig. 2B, lanes 7 and 8). Whereas its
basal activity (i.e., in the absence of RA) was unchanged
(compare lanes 3 and 7), its RA inducibility was virtually
abolished (compare lanes 4 and 8).
The function of the a2 RARE was further investigated by
inserting the directly repeated 5'-GTTCA-3' motifs (Fig. 3A)
upstream of the herpes simplex virus tk promoter, yielding
a2RARE/tk-CAT. The plasmids a2RAREml/tk-CAT,
a2RAREm2/tk-CAT, and a2RAREm3/tk-CAT were simi-
larly constructed using the a2 RARE mutants ml-m3 (Fig.
3A). These reporter genes were transfected into P19 cells
either alone or together with either the parental expression
vector pSG5, as a control (18), or pSG5, expressing either
mRAR-al,
-,/2, or -yl (3, 5, 16, and 19). ,82RARE/tk-CAT,
which contains the human 132 RARE (13) inserted upstream
of the tk promoter ofpBLCAT8+, was used for comparison.
a2RARE/tk-CAT was RA-inducible, albeit to a lesser extent
than 832RARE/tk-CAT (about one-third as efficiently, as
determined by radioactivity counting; Fig. 3B, lanes 1-6),
suggesting that the a2 RARE may have a lower affinity than
the /82 RARE for RARs (see below). The magnitude of the
induction was increased upon cotransfection with mRAR-al,
-,82, or -yl expression vectors (Fig. 3B, lanes 7-12, and data
not shown). In contrast, no RA induction was observed with
the a2 RARE mutants ml-m3 (Fig. 3B, lanes 13-18).
Binding of RAR-a, -13, and
-y to the mRAR-a2 RARE in
Vitro. Binding ofRARs to a2 RARE was investigated in vitro,
using a gel retardation/shift DNA-binding assay and nuclear
extracts prepared from COS-1 monkey cells transiently trans-
fected with vectors expressing either hRAR-al, -/32, or -yl.
Specific retarded complexes (arrow 1 in Fig. 4A) were
observed when a 32P-end-labeled a2 RARE probe was incu-
bated with COS-1 extracts containing any one of the three
hRARs. These complexes were not observed with the mutant
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FIG. 4. Binding of RARs to the a2 RARE in vitro. (A) Specific
binding of hRAR-al, -/2, and -yl to a2 RARE. 32P-end-labeled
oligonucleotides (probe, 10 fmol, 50,000 cpm) corresponding to the
wild-type a2 RARE (lanes 1-7), the mutated a2 RARE ml (lanes
8-14), or the wild-type ,B2 RARE (lanes 15-19) were incubated with
4 ,ug of total protein extract from COS-1 cells transfected with one
of the three hRAR subtypes (al, 82, or l4; see ref. 9) or pSG5 (0),
as indicated. Arrows 1 and 2 point to complexes corresponding to
specific RARE/RAR interactions in the absence (-) or presence (+)
of RAR antibodies specific for either RAR-a, -B, or --y (antiserum),
respectively (see ref. 9). (B) Lower affinity ofRAR for a2 RARE than
for /2 RARE. Extracts of COS-1 cells transfected with hRAR-al
were incubated with 32P-end-labeled probes corresponding to either
the a2 or the /32 RARE, as indicated, and increasing amounts of
nonradioactive ("cold") competitor RARE. Incubations corre-
sponding to lanes 1, 6, 11, and 16 contained no competitors (-);
competitors were added as follows: 10 fmol for lanes 2, 7, 12, and 17;
30 fmol for lanes 3, 8, 13, and 18; 100 fmol for lanes 4, 9, 14, and 19;
300 fmol for lanes 5, 10, 15, and 20.
a2 RARE ml, or with extracts prepared from pSG5 (18)-
transfected cells (Fig. 4A, lanes 1-14). The specificity ofthese
complexes was further demonstrated by using a "supershift"
assay (10) in which antibodies specific for each RAR subtype
were added. In each case a supershifted complex was ob-
served, indicating specific binding of hRARs to a2 RARE
(arrow 2). Specific complexes were seen with a control
32P-end-labeled /2 RARE oligonucleotide, as expected (lanes
15-19).
RAR Binding to a2 RARE Is Weaker Than That to fi2
RARE. The observation that the magnitude ofRA inducibility
of a2RARE/tk-CAT is less than that of /2RARE/tk-CAT
(see above) suggested that RARs may bind to a2 RARE with
a lower affinity than to /32 RARE. Competition experiments
were performed with a2 RARE and /32 RARE oligonucleo-
tides (used either as radiolabeled probes or as nonradioactive
competitors) and cell extracts prepared from COS-1 cells
transfected with hRAR-al. Although both a2 RARE and /32
RARE probes had similar specific activities, a smaller
amount of specific complex was formed with the a2 RARE
than with the 82 RARE oligonucleotide (arrow in Fig. 4B,
compare lanes 1 or 6 with lanes 11 or 16). Moreover, a
nonradioactive a2 RARE oligonucleotide was about one-
third as efficient as the corresponding /32 RARE oligonucle-
otide at competing with either labeled a2 RARE or /32 RARE
probe for binding to hRAR-al (Fig. 4B, compare lanes 1-5
with lanes 6-10, and lanes 11-15 with lanes 16-20). Compe-
tition experiments conducted with extracts prepared from
COS-1 cells transfected with vectors expressing either
hRAR-/32 or hRAR-yl yielded similar results (not shown).
DISCUSSION
A previous paper (3) reported the existence of two major
mouse RAR-a isoforms, mRAR-al and -a2, and observed
that the level of mRAR-a2 transcripts, but not that of
mRAR-al, was increased upon RA treatment of P19 and F9
EC cells (3). Moreover, mRAR-al is ubiquitously expressed,
whereas mRAR-a2 distribution is more restricted (3). It was
also found that the human and mouse RAR-al promoters
resemble those of "housekeeping" genes (3, 20). We show
here that the RA-induced accumulation of mRAR-a2 tran-
script is mediated through an alternative RAR-a promoter
that contains a RARE.
The present sequencing data extend those published pre-
viously (3) and demonstrate that all of the 5' UTR and region
A2 coding sequences are encoded in a single exon (exon E3;
see Fig. 1A and ref. 3). The mRAR-a2 5' UTR (904 bp) is
G+C-rich (>70%) and can form stable hairpin structures (ref.
3 and data not shown). Moreover, it contains a 702-base-long
open reading frame (ORF) preceding the main ORF, which
suggests that this 5' UTR may play a role in the control of
translation efficiency of mRAR-a2 mRNA and/or in its
stability (ref. 3 and references therein). However, this 5' ORF
is not conserved in the hRAR-a2 5' UTR (our unpublished
results).
There is no consensus TATA box 30 bp upstream from the
mRAR-a2 (and hRAR-a2) start site, but an A+T-rich se-
quence is present at this position. It may correspond to a
degenerate TATA box, in view of its conservation in the
hRAR-a2 promoter and in the highly similar RAR-/32 pro-
moter (see below and Fig. 1C). There are several putative
binding sites for the Spl factor (21) in the mRAR-a2 5' region
(Fig. 1A). Whether they contribute to the basal activity of the
RAR-a2 promoter remains to be investigated.
The most interesting feature of the mRAR-a2 proximal
promoter sequence is the presence of a RARE consisting of
the directly repeated motif, 5'-GTTCA-3', with 6 intervening
bases. The role of these motifs in mediating the RA response
is demonstrated by the detrimental effect of their mutation on
RA inducibility ofreporter genes containing either the natural
mRAR-a2 promoter (Fig. 2B) or the heterologous tk pro-
moter (Fig. 3). Furthermore, our in vitro studies demonstrate
that all three RARs bind specifically to the a2 RARE (Fig.
4A). The mouse a2 RARE, whose sequence and location are
conserved in the hRAR-a2 5' flanking region, is strikingly
similar to that of the human (13) and mouse (12) /2 RAREs,
in both sequence and location (Fig. 1C). However, the /32
RARE is -3-fold more efficient than its a2 counterpart for
both RA inducibility in vivo (Fig. 3B) and RAR binding in
vitro (Fig. 4B), which further supports the conclusion that
these RAREs mediate RA-dependent transcriptional induc-
tion.
The above results indicate that the spacer sequence located
between the GTTCA repeated motifs and/or the bases flank-
ing these motifs must modulate RARE "strength." We have
changed either the intervening or the flanking bases of a2
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FIG. 5. Sequence similarities between RAREs. The nucleotide
sequences ofRAREs present in the promoter region of several genes
are aligned: mouse and human RAR-a2, the mouse (5, 12) and human
(13) RAR-.32, human alcohol dehydrogenase 3 (hADH3; ref. 22),
mouse cellular retinol-binding protein I (mCRBPI; ref. 10), and
human apolipoprotein Al (hapoAl; ref. 23). Conserved nucleotides
are boxed, and directly repeated 5'-GTTCA-3' motifs are indicated
by two arrows. A consensus RARE sequence is derived (see text).
RARE to those of 82 RARE and found that both of them
contribute equally to the above 3-fold difference (P.L. and
P.C., unpublished results). We note that other natural
RAREs contain a direct repetition of either the GTTCA motif
or the related motif GGTCA (Fig. 5; see refs. 9 and 10),
whereas the length and the bases of the spacer sequence as
well as the flanking bases are not conserved. Nevertheless,
a consensus sequence can be derived, 5'-GAGGTCAX,(o3)-
AGAGTTCA-3' (where X is A, C, T, or G). Further studies
AG G
are required to define precisely the contribution of each base
of this consensus sequence to RARE strength. An additional
GGTCA motif located further upstream of the RARE is
present in both the RAR-a2 and RAR-/82 promoters (see Fig.
1 A and C). Whether this single motif cooperates with the
RARE to mediate RA inducibility is unknown. Interestingly,
this motif is contained within the sequence 5'-TGGG-
TGGGTCA-3', which is conserved in the mRAR-,82 pro-
moter (see Fig. 1) and is also present in the proximal region
of the ovalbumin gene promoter, where it has been shown to
be a weak estrogen response element (24) and also to mediate
the activity of the transcription factor AP-1 (25).
Previous reports (1-3, 5) have stressed similarities in the
overall structural organization of the three RAR genes, as
well as similarities between the amino acid sequences of the
N-terminal A regions of the isoforms transcribed from the
upstream P1 promoters (al, ,31/,33, and 'yl), on the one hand,
and of those transcribed from the downstream P2 promoters
(a2, 832, and 'y2) on the other (1, 2). Our present results
support the idea that the RAR-a2 and RAR-,82 transcription
units were derived by duplication of a common ancestor.
However, the RAR-y2 isoform is not RA-inducible (16),
which suggests that it originated from a duplication event that
preceded the RAR-a/,8 duplication. Thus the primordial
RAR gene may have had two promoters, a RA-noninducible
upstream promoter (P1) and a RA-inducible downstream
promoter (P2), and the inducibility of the RAR-y2 P2 pro-
moter would have been lost. In any event, the question arises
as to which RAR subtypes and isoforms can mediate the RA
induction of the a2 promoter. All three RARs can bind to the
mRAR-a2 RARE in vitro and transactivate a2RARE/tk-
CAT reporter genes in cultured cells. It remains to be seen
whether these RAR properties hold true under "natural"
conditions within the context of the RAR-a2 promoter, and
in cells and tissues where the expression of the RAR-a2
isoform is controlled by RA during development and in adult
vertebrates.
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RAREs
mRAR-cW
hRAR-oe
mRAR-02
hRAR-02
hADH3
mCRBPI
-TTCII3C(
(-59) 5'-GGCG
(-58) 5'-GGCG.
(-57) 5'-GAAGC
(-57) 5' -GTAGC
(-280) 5 '-ACAG.
(-1015) 5 '-TAGTP
3TTC)
hapoAl (-195) 5' -GCAG
Consensus 5 -Gj
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d.=cAGTGGG-3- (-217)
